

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 5/4/1993
Gender: Female
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

Plasminogen Activator Inhibitor-1, PAI-1 (SERPINE1) Genotyping

ARUP test code 2004980

PAI-1 Specimen whole Blood

PAI-1 Interpretation 5G/5G

Indication for testing: Assess genetic risk for thrombosis.

Result: PAI-1 Genotype 5G/5G

Interpretation: Two copies of the PAI-1 5G allele (5G/5G) were detected. The 4G allele, which is associated with increased PAI-1 plasma activity levels, was not detected. This result does not exclude other genetic, or non-genetic, causes for thrombosis.

Recommendations: If clinically indicated, testing for other inherited or acquired thrombophilic disorders is recommended. For additional testing information, refer to the Antiphospholipid Syndrome, Hypercoagulable States, Thrombophilia, or Venous Thromboembolism topics at arupconsult.com.

This result has been reviewed and approved by [REDACTED]

H=High, L=Low, *=Abnormal, C=Critical

Background Information: Plasminogen Activator Inhibitor-1, PAI-1 (SERPINE1) Genotyping:

Characteristics: The 4G allele within in the promoter region of the PAI-1 (SERPINE1) gene is associated with higher plasma PAI-1 activity when compared with the 5G allele. Heterozygosity or homozygosity for the 4G allele confers a risk for venous thromboembolism (VTE), especially in individuals with other thrombophilic risk factors, as well as a risk for myocardial infarction.

Frequency of the 4G Allele: Caucasian 0.52, Hispanic 0.38, African-American 0.13-0.28.

Variant Tested: The PAI-1 promoter 4G/5G polymorphism located in the promoter region of the SERPINE1 gene. NM_000602.3(SERPINE1) c.-817dupG (from start of translation).

Inheritance: Autosomal dominant.

Clinical sensitivity: Unknown.

Methodology: Polymerase chain reaction and fluorescence monitoring.

Analytical Sensitivity and Specificity: 99 percent.

Limitations: Variants in the PAI-1 (SERPINE1) gene, other than the 4G/5G polymorphism, are not evaluated. Diagnostic errors can occur due to rare sequence variations.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
PAI-1 Specimen	24-142-129610	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
PAI-1 Interpretation	24-142-129610	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical